Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)
Reviewed 6 sourcesPublished by PepVault
Tirzepatide doses from 2.5 to 15 mg: the Mounjaro and Zepbound label steps, the 4-week rule, maintenance doses, pens and vials, and SURMOUNT-1 weight by dose.

- Last reviewed
- Sources
- 6
- Questions
- 8
- Compounds
- 1
The short answer
Tirzepatide is injected once a week. Both labels start at 2.5 mg and step up 2.5 mg at a time, with at least four weeks on each dose: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Zepbound's maintenance doses are 5, 10 or 15 mg, and 15 mg is the maximum. In SURMOUNT-1, weight fell 15.0%, 19.5% and 20.9% at 72 weeks on 5, 10 and 15 mg.
Evidence: FDA prescribing information for Zepbound and Mounjaro (dosing, presentations and the trial tables in section 14), and randomised, double-blind phase 3 trials in people (SURMOUNT-1, SURMOUNT-2 and SURPASS-1); tirzepatide is FDA-approved.

What are the tirzepatide doses?
There are six doses, 2.5 mg apart, and every one is a once-weekly injection under the skin. The table shows each step at the label's fastest pace, four weeks a step, and what each label does with it12. The week column is the earliest a step can come, not a timetable: the label sets a minimum of four weeks on a dose, never a maximum12.
| Weekly dose | Earliest weeks | Zepbound (weight, sleep apnea) | Mounjaro (type 2 diabetes) |
|---|---|---|---|
| 2.5 mg | 1–4 | The starting dose for every use; not approved as a maintenance dose1 | The starting dose2 |
| 5 mg | 5–8 | The first step, and the lowest maintenance dose for weight1 | A step, if more glucose control is needed2 |
| 7.5 mg | 9–12 | A step on the way up1 | A step2 |
| 10 mg | 13–16 | A maintenance dose for weight and for sleep apnea1 | A step; the maximum for children 10 and older2 |
| 12.5 mg | 17–20 | A step on the way up1 | A step2 |
| 15 mg | 21 on | A maintenance dose for weight and for sleep apnea, and the maximum1 | The maximum in adults2 |

These are the labels' schedules, not a dose for any one person. The starting dose, each step and the dose someone stays on are the prescriber's decision, made on how the treatment is working and how it is tolerated1.

What rules does the label set around each step?
- At least four weeks per dose. Zepbound goes from 2.5 mg to 5 mg after four weeks, then may rise 2.5 mg at a time after at least four weeks on the current dose. The label sets this climb to lower the risk of stomach side effects1.
- The maintenance dose is the weekly dose someone stays on. For weight it is 5, 10 or 15 mg; for obstructive sleep apnea, 10 or 15 mg. The choice weighs response and tolerability, and if a maintenance dose is not tolerated, the label says to consider a lower one1.
- Mounjaro climbs only when needed. It starts at 2.5 mg and steps up 2.5 mg, after at least four weeks, if more glucose control is needed, up to 15 mg in adults and 10 mg in children 10 and older2.
- 15 mg is the ceiling for adults on both brands; Mounjaro's ceiling in children 10 and older is 10 mg12.
- A missed dose is taken as soon as possible within four days (96 hours); after more than four days it is skipped and the next dose goes on the usual day. The missed-dose tool on our site walks through it12.
- Moving the dose day is allowed as long as at least three days (72 hours) separate the two doses12.
- One tirzepatide at a time. Zepbound is not meant to be combined with another tirzepatide product, such as Mounjaro, or with any GLP-1 drug1.
In PepVault you enter the dose steps from your prescription; when your schedule reaches the next one, Today offers the step-up for you to confirm, and nothing changes until you do. Set reminders in PepVault
Its reminder comes at the time you set on dose day, and the log keeps each weekly dose as you took it, so the step you are on stays on record. Set reminders in PepVault
Why at least four weeks on each dose?
Two reasons sit in the label. The first is the stomach: the slow climb is there to lower the risk of nausea, vomiting and diarrhoea, which came mostly during the dose climb in the trials and eased over time1. The second is the drug level. Tirzepatide's half-life is about five to six days, the level builds with each weekly dose and reaches a steady state after four weeks, and exposure rises in proportion to the dose1. So four weeks is about how long each new dose takes to settle at its full level. The chart shows that build-up.
Try it
How Tirzepatide builds up
An estimate from a half-life of about 5 days, one dose a week for four weeks. The shape of the level, not a measurement.
Mounjaro or Zepbound: are the doses the same?
Yes. Both are tirzepatide from Eli Lilly, in the same six strengths, with the same 2.5 mg steps and the same 15 mg ceiling in adults12. What differs is the use. Mounjaro, first approved on May 13, 20226, treats type 2 diabetes alongside diet and exercise, in adults and in children 10 and older, and lowers the risk of major heart and stroke events in adults with type 2 diabetes at high risk of them2. Zepbound, first approved on November 8, 20235, is for reducing excess weight and keeping it off in adults with obesity, or with overweight and at least one weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity1.
The other difference is the starting dose's role. Zepbound's label says 2.5 mg is for starting only, and lists the doses to stay on. Mounjaro's label lists no maintenance doses: it steps up when more glucose control is needed12.
Which pens and vials exist, and how much is in each?
As of November 2026, both labels list the same four presentations, each in all six strengths12. A single-dose pen or vial holds one weekly dose; the multi-dose vial and the single-patient-use KwikPen each hold four12.
| Presentation | Doses in each | Liquid per dose | Strengths |
|---|---|---|---|
| Single-dose pen | 1 | 0.5 mL | 2.5, 5, 7.5, 10, 12.5 or 15 mg per 0.5 mL12 |
| Single-dose vial | 1 | 0.5 mL | 2.5, 5, 7.5, 10, 12.5 or 15 mg per 0.5 mL12 |
| Multi-dose vial | 4 | 0.6 mL | From 10 mg in 2.4 mL (4.17 mg/mL) for four 2.5 mg doses to 60 mg in 2.4 mL (25 mg/mL) for four 15 mg doses12 |
| Single-patient-use KwikPen | 4 | Set by the pen | The same totals as the multi-dose vial, 10 to 60 mg in 2.4 mL12 |

Each strength is its own pen or vial, so a step from 5 mg to 7.5 mg means the 7.5 mg pen or vial12. Vials are drawn with a 1 mL syringe that can measure a 0.5 or 0.6 mL dose, with a new syringe and needle every time12. An opened multi-dose vial or KwikPen is thrown away after four weekly doses, 30 days after first use or 30 days in total at room temperature, even with liquid left in it1. Where to inject is covered in our injection-site guide.
How much weight was lost on each dose in SURMOUNT-1?
SURMOUNT-1 assigned 2,539 adults with obesity, or overweight and a weight-related condition, and without diabetes, to 5, 10 or 15 mg or placebo for 72 weeks, including a dose climb of up to 20 weeks; everyone also had diet and activity counselling13. They started at about 231 lb (104.8 kg) on average3. Each group climbed 2.5 mg every four weeks to its assigned dose and stayed there4. The figures count everyone who was assigned, whether or not they kept taking it13.
| At week 72 | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Average weight change | −3.1% | −15.0% | −19.5% | −20.9% |
| Lost at least 5% | 34.5% | 85.1% | 88.9% | 90.9% |
| Lost at least 10% | 18.8% | 68.5% | 78.1% | 83.5% |
| Lost at least 15% | 8.8% | 48.0% | 66.6% | 70.6% |
| Lost at least 20% | 3.1% | 30.0% | 50.1% | 56.7% |
| Stopped the study drug | 26.4% | 14.3% | 16.4% | 15.1% |

Source for the table: the Zepbound label's Table 2 and its Study 1 results1. The biggest jump is from 5 to 10 mg, about 4.5 points on average; 10 to 15 mg added about 1.4 more. The lowest maintenance dose still reached 15% on average, and the share losing a fifth of their weight went from 30% on 5 mg to 57% on 15 mg1. In people with type 2 diabetes (SURMOUNT-2, Study 2 in the label, which had no 5 mg group), 10 and 15 mg gave 12.8% and 14.7%, against 3.2% on placebo1. How the loss builds week by week is in our tirzepatide week-by-week guide and the weight loss by week tool.
What did the Mounjaro trial see by dose?
SURPASS-1 gave 478 adults with type 2 diabetes, on diet and exercise alone, 5, 10 or 15 mg or placebo for 40 weeks. HbA1c, the blood test for average glucose over about three months, started near 8.0%2.
| At week 40 | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| HbA1c change (points) | −0.1 | −1.8 | −1.7 | −1.7 |
| Reached HbA1c below 7% | 23% | 82% | 85% | 78% |
| Weight change | −1.0 kg (2.2 lb) | −6.3 kg (13.9 lb) | −7.0 kg (15.4 lb) | −7.8 kg (17.2 lb) |
In this trial the glucose effect was about the same on every dose, while weight loss grew with the dose2. Mounjaro's label ties each step to glucose, not weight: it steps up only when more glucose control is needed2.
Do side effects change with the dose?
The stomach effects are the common ones, and they come mostly during the dose climb: in the Zepbound label's two weight trials, nausea affected 25%, 29% and 28% on 5, 10 and 15 mg, against 8% on placebo (the 5 mg figure is from SURMOUNT-1 alone)1. The guide Mounjaro and Zepbound side effects by dose has every rate at each step and what helps. Stomach pain that is severe and does not go away, sometimes reaching the back, is the one to call a doctor about straight away1.
Commonly reported: nausea or tiredness for a day or two after the injection, mostly after a dose increase, easing as the weeks on a dose go by.
Sources
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. dailymed.nlm.nih.gov
- Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. PubMed 35658024
- ClinicalTrials.gov NCT04184622. A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1; sponsor Eli Lilly and Company). Arm descriptions. clinicaltrials.gov
- U.S. Food and Drug Administration. FDA approves new medication for chronic weight management (Zepbound). News release, November 8, 2023. fda.gov
- U.S. Food and Drug Administration. Drugs@FDA: MOUNJARO, NDA 215866, original approval May 13, 2022. accessdata.fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.